Malignant Glioma Therapeutics Market, Global Outlook and Forecast 2022-2028

March 2022 | 62 pages | ID: M3E84ED1ABEBEN
Market Monitor Global

Abstracts

Malignant glioma, a tumor derived from the nerve epithelium, is generally referred to as glioma, accounting for 40-50% of brain tumors, and is the most common intracranial malignant tumor.

This report contains market size and forecasts of Malignant Glioma Therapeutics in Global, including the following market information:

Global Malignant Glioma Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Malignant Glioma Therapeutics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Chemotherapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Malignant Glioma Therapeutics include Merck, Roche, Arbor Pharmaceuticals, Pfizer, AbbVie, Amgen, Bristol-Myers Squibb, Sun Pharmaceuticals and Teva and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Malignant Glioma Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Malignant Glioma Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Malignant Glioma Therapeutics Market Segment Percentages, by Type, 2021 (%)

• Chemotherapy
• Radiotherapy
• Targeted therapy

Global Malignant Glioma Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Malignant Glioma Therapeutics Market Segment Percentages, by Application, 2021 (%)

• Adult
• Children

Global Malignant Glioma Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Malignant Glioma Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Malignant Glioma Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Malignant Glioma Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Merck
• Roche
• Arbor Pharmaceuticals
• Pfizer
• AbbVie
• Amgen
• Bristol-Myers Squibb
• Sun Pharmaceuticals
• Teva
• Emcure

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Malignant Glioma Therapeutics Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Malignant Glioma Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL MALIGNANT GLIOMA THERAPEUTICS OVERALL MARKET SIZE

2.1 Global Malignant Glioma Therapeutics Market Size: 2021 VS 2028
2.2 Global Malignant Glioma Therapeutics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Malignant Glioma Therapeutics Players in Global Market
3.2 Top Global Malignant Glioma Therapeutics Companies Ranked by Revenue
3.3 Global Malignant Glioma Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Malignant Glioma Therapeutics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Malignant Glioma Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Malignant Glioma Therapeutics Players in Global Market
  3.6.1 List of Global Tier 1 Malignant Glioma Therapeutics Companies
  3.6.2 List of Global Tier 2 and Tier 3 Malignant Glioma Therapeutics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Malignant Glioma Therapeutics Market Size Markets, 2021 & 2028
  4.1.2 Chemotherapy
  4.1.3 Radiotherapy
  4.1.4 Targeted therapy
4.2 By Type - Global Malignant Glioma Therapeutics Revenue & Forecasts
  4.2.1 By Type - Global Malignant Glioma Therapeutics Revenue, 2017-2022
  4.2.2 By Type - Global Malignant Glioma Therapeutics Revenue, 2023-2028
  4.2.3 By Type - Global Malignant Glioma Therapeutics Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Malignant Glioma Therapeutics Market Size, 2021 & 2028
  5.1.2 Adult
  5.1.3 Children
5.2 By Application - Global Malignant Glioma Therapeutics Revenue & Forecasts
  5.2.1 By Application - Global Malignant Glioma Therapeutics Revenue, 2017-2022
  5.2.2 By Application - Global Malignant Glioma Therapeutics Revenue, 2023-2028
  5.2.3 By Application - Global Malignant Glioma Therapeutics Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Malignant Glioma Therapeutics Market Size, 2021 & 2028
6.2 By Region - Global Malignant Glioma Therapeutics Revenue & Forecasts
  6.2.1 By Region - Global Malignant Glioma Therapeutics Revenue, 2017-2022
  6.2.2 By Region - Global Malignant Glioma Therapeutics Revenue, 2023-2028
  6.2.3 By Region - Global Malignant Glioma Therapeutics Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Malignant Glioma Therapeutics Revenue, 2017-2028
  6.3.2 US Malignant Glioma Therapeutics Market Size, 2017-2028
  6.3.3 Canada Malignant Glioma Therapeutics Market Size, 2017-2028
  6.3.4 Mexico Malignant Glioma Therapeutics Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Malignant Glioma Therapeutics Revenue, 2017-2028
  6.4.2 Germany Malignant Glioma Therapeutics Market Size, 2017-2028
  6.4.3 France Malignant Glioma Therapeutics Market Size, 2017-2028
  6.4.4 U.K. Malignant Glioma Therapeutics Market Size, 2017-2028
  6.4.5 Italy Malignant Glioma Therapeutics Market Size, 2017-2028
  6.4.6 Russia Malignant Glioma Therapeutics Market Size, 2017-2028
  6.4.7 Nordic Countries Malignant Glioma Therapeutics Market Size, 2017-2028
  6.4.8 Benelux Malignant Glioma Therapeutics Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Malignant Glioma Therapeutics Revenue, 2017-2028
  6.5.2 China Malignant Glioma Therapeutics Market Size, 2017-2028
  6.5.3 Japan Malignant Glioma Therapeutics Market Size, 2017-2028
  6.5.4 South Korea Malignant Glioma Therapeutics Market Size, 2017-2028
  6.5.5 Southeast Asia Malignant Glioma Therapeutics Market Size, 2017-2028
  6.5.6 India Malignant Glioma Therapeutics Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Malignant Glioma Therapeutics Revenue, 2017-2028
  6.6.2 Brazil Malignant Glioma Therapeutics Market Size, 2017-2028
  6.6.3 Argentina Malignant Glioma Therapeutics Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Malignant Glioma Therapeutics Revenue, 2017-2028
  6.7.2 Turkey Malignant Glioma Therapeutics Market Size, 2017-2028
  6.7.3 Israel Malignant Glioma Therapeutics Market Size, 2017-2028
  6.7.4 Saudi Arabia Malignant Glioma Therapeutics Market Size, 2017-2028
  6.7.5 UAE Malignant Glioma Therapeutics Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Merck
  7.1.1 Merck Corporate Summary
  7.1.2 Merck Business Overview
  7.1.3 Merck Malignant Glioma Therapeutics Major Product Offerings
  7.1.4 Merck Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
  7.1.5 Merck Key News
7.2 Roche
  7.2.1 Roche Corporate Summary
  7.2.2 Roche Business Overview
  7.2.3 Roche Malignant Glioma Therapeutics Major Product Offerings
  7.2.4 Roche Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
  7.2.5 Roche Key News
7.3 Arbor Pharmaceuticals
  7.3.1 Arbor Pharmaceuticals Corporate Summary
  7.3.2 Arbor Pharmaceuticals Business Overview
  7.3.3 Arbor Pharmaceuticals Malignant Glioma Therapeutics Major Product Offerings
  7.3.4 Arbor Pharmaceuticals Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
  7.3.5 Arbor Pharmaceuticals Key News
7.4 Pfizer
  7.4.1 Pfizer Corporate Summary
  7.4.2 Pfizer Business Overview
  7.4.3 Pfizer Malignant Glioma Therapeutics Major Product Offerings
  7.4.4 Pfizer Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
  7.4.5 Pfizer Key News
7.5 AbbVie
  7.5.1 AbbVie Corporate Summary
  7.5.2 AbbVie Business Overview
  7.5.3 AbbVie Malignant Glioma Therapeutics Major Product Offerings
  7.5.4 AbbVie Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
  7.5.5 AbbVie Key News
7.6 Amgen
  7.6.1 Amgen Corporate Summary
  7.6.2 Amgen Business Overview
  7.6.3 Amgen Malignant Glioma Therapeutics Major Product Offerings
  7.6.4 Amgen Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
  7.6.5 Amgen Key News
7.7 Bristol-Myers Squibb
  7.7.1 Bristol-Myers Squibb Corporate Summary
  7.7.2 Bristol-Myers Squibb Business Overview
  7.7.3 Bristol-Myers Squibb Malignant Glioma Therapeutics Major Product Offerings
  7.7.4 Bristol-Myers Squibb Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
  7.7.5 Bristol-Myers Squibb Key News
7.8 Sun Pharmaceuticals
  7.8.1 Sun Pharmaceuticals Corporate Summary
  7.8.2 Sun Pharmaceuticals Business Overview
  7.8.3 Sun Pharmaceuticals Malignant Glioma Therapeutics Major Product Offerings
  7.8.4 Sun Pharmaceuticals Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
  7.8.5 Sun Pharmaceuticals Key News
7.9 Teva
  7.9.1 Teva Corporate Summary
  7.9.2 Teva Business Overview
  7.9.3 Teva Malignant Glioma Therapeutics Major Product Offerings
  7.9.4 Teva Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
  7.9.5 Teva Key News
7.10 Emcure
  7.10.1 Emcure Corporate Summary
  7.10.2 Emcure Business Overview
  7.10.3 Emcure Malignant Glioma Therapeutics Major Product Offerings
  7.10.4 Emcure Malignant Glioma Therapeutics Revenue in Global Market (2017-2022)
  7.10.5 Emcure Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Malignant Glioma Therapeutics Market Opportunities & Trends in Global Market
Table 2. Malignant Glioma Therapeutics Market Drivers in Global Market
Table 3. Malignant Glioma Therapeutics Market Restraints in Global Market
Table 4. Key Players of Malignant Glioma Therapeutics in Global Market
Table 5. Top Malignant Glioma Therapeutics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Malignant Glioma Therapeutics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Malignant Glioma Therapeutics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Malignant Glioma Therapeutics Product Type
Table 9. List of Global Tier 1 Malignant Glioma Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Malignant Glioma Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Malignant Glioma Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Malignant Glioma Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Malignant Glioma Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Malignant Glioma Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Malignant Glioma Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Malignant Glioma Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Malignant Glioma Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Malignant Glioma Therapeutics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Malignant Glioma Therapeutics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Malignant Glioma Therapeutics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Malignant Glioma Therapeutics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Malignant Glioma Therapeutics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Malignant Glioma Therapeutics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Malignant Glioma Therapeutics Revenue, (US$, Mn), 2023-2028
Table 30. Merck Corporate Summary
Table 31. Merck Malignant Glioma Therapeutics Product Offerings
Table 32. Merck Malignant Glioma Therapeutics Revenue (US$, Mn), (2017-2022)
Table 33. Roche Corporate Summary
Table 34. Roche Malignant Glioma Therapeutics Product Offerings
Table 35. Roche Malignant Glioma Therapeutics Revenue (US$, Mn), (2017-2022)
Table 36. Arbor Pharmaceuticals Corporate Summary
Table 37. Arbor Pharmaceuticals Malignant Glioma Therapeutics Product Offerings
Table 38. Arbor Pharmaceuticals Malignant Glioma Therapeutics Revenue (US$, Mn), (2017-2022)
Table 39. Pfizer Corporate Summary
Table 40. Pfizer Malignant Glioma Therapeutics Product Offerings
Table 41. Pfizer Malignant Glioma Therapeutics Revenue (US$, Mn), (2017-2022)
Table 42. AbbVie Corporate Summary
Table 43. AbbVie Malignant Glioma Therapeutics Product Offerings
Table 44. AbbVie Malignant Glioma Therapeutics Revenue (US$, Mn), (2017-2022)
Table 45. Amgen Corporate Summary
Table 46. Amgen Malignant Glioma Therapeutics Product Offerings
Table 47. Amgen Malignant Glioma Therapeutics Revenue (US$, Mn), (2017-2022)
Table 48. Bristol-Myers Squibb Corporate Summary
Table 49. Bristol-Myers Squibb Malignant Glioma Therapeutics Product Offerings
Table 50. Bristol-Myers Squibb Malignant Glioma Therapeutics Revenue (US$, Mn), (2017-2022)
Table 51. Sun Pharmaceuticals Corporate Summary
Table 52. Sun Pharmaceuticals Malignant Glioma Therapeutics Product Offerings
Table 53. Sun Pharmaceuticals Malignant Glioma Therapeutics Revenue (US$, Mn), (2017-2022)
Table 54. Teva Corporate Summary
Table 55. Teva Malignant Glioma Therapeutics Product Offerings
Table 56. Teva Malignant Glioma Therapeutics Revenue (US$, Mn), (2017-2022)
Table 57. Emcure Corporate Summary
Table 58. Emcure Malignant Glioma Therapeutics Product Offerings
Table 59. Emcure Malignant Glioma Therapeutics Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Malignant Glioma Therapeutics Segment by Type in 2021
Figure 2. Malignant Glioma Therapeutics Segment by Application in 2021
Figure 3. Global Malignant Glioma Therapeutics Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Malignant Glioma Therapeutics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Malignant Glioma Therapeutics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Malignant Glioma Therapeutics Revenue in 2021
Figure 8. By Type - Global Malignant Glioma Therapeutics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Malignant Glioma Therapeutics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Malignant Glioma Therapeutics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Malignant Glioma Therapeutics Revenue Market Share, 2017-2028
Figure 12. US Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Malignant Glioma Therapeutics Revenue Market Share, 2017-2028
Figure 16. Germany Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 17. France Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Malignant Glioma Therapeutics Revenue Market Share, 2017-2028
Figure 24. China Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 28. India Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Malignant Glioma Therapeutics Revenue Market Share, 2017-2028
Figure 30. Brazil Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Malignant Glioma Therapeutics Revenue Market Share, 2017-2028
Figure 33. Turkey Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Malignant Glioma Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 37. Merck Malignant Glioma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Roche Malignant Glioma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Arbor Pharmaceuticals Malignant Glioma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Pfizer Malignant Glioma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. AbbVie Malignant Glioma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Amgen Malignant Glioma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Bristol-Myers Squibb Malignant Glioma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Sun Pharmaceuticals Malignant Glioma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Teva Malignant Glioma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Emcure Malignant Glioma Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)